AP Insights, News, Videos, and More

Engaging in regular physical activity has been linked with reduced illicit substance and alcohol use among individuals in recovery, according to review of 43 past studies published this week.

Rx Summit presenters Kelley McNichols, PhD, LPC, NCC, CADC, CCDP, CCTP, and Mike Krafick, CRS, CRSS, discuss the value of intercept initiatives that help individuals in underserved areas.

In a new study backed by NIDA, a strong association has been identified between prevalence of prescription stimulant therapy for attention-deficit/hyperactivity disorder (ADHD) and rates of stimulant misuse among middle and high school...

For the first time in the 12-year history of the Rx and Illicit Drug Summit, the topic of overdose prevention centers took center stage on Thursday morning, with stakeholders involved with OPCs in the US convening for a panel.

At the Rx Summit on Wednesday, officials from the Drug Enforcement Administration (DEA) outlined the fentanyl crisis plaguing the United States and explained how the organizations fueling it are strengthening their operations—and how DEA is...

ONDCP Director Rahul Gupta, MD, MPH, MBA, FACP, announced during an Rx Summit plenary session on Wednesday that fentanyl combined with xylazine has been designated as an emerging threat to the United States.

With deaths involving fentanyl and xylazine rising, NIDA Director Nora Volkow, MD, NIH Director Lawrence Tabak, DDS, PhD, and NIAAA Director George Koob, PhD, presented research updates and developments in substance use disorder treatment to...

Border security and the nation’s growing fentanyl epidemic were at the forefront of a cordial, but spirited panel discussion among members of Congress during the Tuesday morning plenary session at the Rx and Illicit Drug Summit in Atlanta,...